Trials / Completed
CompletedNCT06169085
Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants
A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate Pharmacokinetics, Safety and Tolerability of RAY1216 in Elder Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability and PK of Leritrelvir in elder participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leritrelvir | Oral |
Timeline
- Start date
- 2023-08-24
- Primary completion
- 2023-09-20
- Completion
- 2023-10-11
- First posted
- 2023-12-13
- Last updated
- 2024-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06169085. Inclusion in this directory is not an endorsement.